Matthew K Lee, MD
Otolaryngology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Cedars-Sinai Medical Care Foundation · 1,684 clinicians in this group
Hospitals listed: Cedars-Sinai Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lee’s office at (310) 423-0674 to ask if they take your plan before you enroll.
California Medical Board record
Licence A116546 · Current
Licensed to practise in California · since 2011 · expires 2028-09-30 · Boston University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Cedars-Sinai Medical CenterLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Postoperative sepsis rate: 7.77 (6.11 to 9.44) · 6,132 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.2 to 14.7) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 134.15 (109.33 to 158.98) · 557 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.386, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.661, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.628, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.503, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.8 (3 to 4.8) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.8) · 2,580 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Cedars-Sinai Medical Center
Behind the star rating — Deaths: 7 better, 1 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 7.77 (6.11 to 9.44) · 6,132 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.2 to 14.7) · 1,174 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.15 (109.33 to 158.98) · 557 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.386 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.661 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.628 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.8 (3 to 4.8) · 1,174 cases | Better | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.8) · 2,580 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.66 (0.06 to 1.25) · 8,257 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.92 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 223 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.9 · 191 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.3 · 409 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.5 · 1,544 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.5 · 1,742 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 549 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 9,504 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.28) · 29,170 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.05 to 0.32) · 31,661 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.1 (3.06 to 5.14) · 11,199 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.47 to 2.29) · 6,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.24 to 2.86) · 10,075 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.2 (5.76 to 10.65) · 6,012 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.91 (0.72 to 3.11) · 2,803 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.75 (0.47 to 1.03) · 27,865 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 472 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.437 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.168 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 492 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 1,750 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.9 · 498 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5.8 · 1,908 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 1,850 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,572 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.7 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 172 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 240 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.1 to 17.5) · 1,197 cases | No different | Jan 2022 – Dec 2024 |
What patients said (1,081 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$45,440
Medicare paid this office $45,440 for 98 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 41 | $5,278 | $103 |
| New patient visit (45+ min) | 25 | $3,341 | $134 |
| Short return visit (20+ min) | 26 | $2,292 | $72 |
| Diagnostic exam of nasal passages using an endoscope | 13 | $2,079 | $160 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
98 Original Medicare patients in 2024. Average age 72 · Women 62% · Also on Medicaid 30% · Health risk score 1.53. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 62% · Coronary heart disease 41% · Depression 32% · Diabetes 29% · Heart failure 21% · COPD 21% · Chronic kidney disease 16% · Cancer 16% · Atrial fibrillation 15%.
The office billed $242,092, Medicare allowed $58,238 and paid $45,440; for 823 services of 38 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 98 | 823 | 72 | 1.53 | $242,092 | $45,440 |
| 2023 | 98 | 773 | 74 | 1.39 | $182,844 | $42,436 |
| 2022 | 152 | 1,111 | 74 | 1.52 | $245,143 | $50,243 |
| 2021 | 195 | 988 | 73 | 1.23 | $197,593 | $45,177 |
| 2020 | 182 | 332 | 72 | 1.69 | $139,643 | $33,792 |
| 2019 | 268 | 547 | 73 | 1.61 | $254,823 | $59,891 |
| 2018 | 316 | 575 | 73 | 1.59 | $229,710 | $54,356 |
| 2017 | 337 | 582 | 73 | 1.74 | $228,531 | $54,317 |
| 2016 | 48 | 77 | 73 | 1.08 | $20,524 | $5,293 |
| 2015 | 24 | 34 | 65 | 0.99 | $20,650 | $3,832 |
| 2014 | 12 | 14 | 65 | 0.97 | $9,886 | $1,840 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 45 | $5,679 | $109 |
| Short return visit (20+ min) | 31 | $2,692 | $73 |
| Diagnostic exam of nasal passages using an endoscope | 16 | $2,625 | $164 |
| New patient visit (45+ min) | 18 | $2,315 | $129 |
| New patient visit (30+ min) | 16 | $1,387 | $87 |
2022: 7 services
| Return visit (30+ min) | 61 | $6,733 | $100 |
| Short return visit (20+ min) | 46 | $4,729 | $74 |
| New patient visit (45+ min) | 31 | $4,021 | $130 |
| Diagnostic exam of voice box using a flexible endoscope | 24 | $2,665 | $103 |
| Diagnostic exam of nasal passages using an endoscope | 14 | $2,230 | $149 |
| New patient visit (30+ min) | 24 | $1,930 | $80 |
| Removal of impacted ear wax | 16 | $610 | $32 |
2021: 8 services
| Return visit (30+ min) | 73 | $9,147 | $103 |
| New patient visit (45+ min) | 52 | $7,183 | $138 |
| Short return visit (20+ min) | 43 | $3,819 | $72 |
| Diagnostic exam of voice box using a flexible endoscope | 28 | $3,207 | $100 |
| New patient visit (30+ min) | 39 | $3,198 | $82 |
| Diagnostic exam of nasal passages using an endoscope | 12 | $2,608 | $186 |
| Removal of impacted ear wax | 17 | $771 | $35 |
| Exam of ear using a microscope | 12 | $333 | $24 |
2020: 6 services
| Return visit (30+ min) | 64 | $6,976 | $89 |
| New patient visit (45+ min) | 34 | $4,857 | $143 |
| New patient visit (30+ min) | 49 | $4,338 | $89 |
| Diagnostic exam of voice box using a flexible endoscope | 31 | $3,195 | $100 |
| Diagnostic exam of nasal passages using an endoscope | 16 | $2,603 | $153 |
| Short return visit (20+ min) | 34 | $2,287 | $60 |
2019: 7 services
| Return visit (30+ min) | 115 | $13,072 | $89 |
| New patient visit (45+ min) | 83 | $10,958 | $132 |
| Diagnostic exam of voice box using a flexible endoscope | 51 | $5,736 | $102 |
| Diagnostic exam of nasal passages using an endoscope | 33 | $5,681 | $172 |
| New patient visit (30+ min) | 47 | $4,145 | $88 |
| Short return visit (20+ min) | 48 | $3,541 | $61 |
| Complex control of nose bleed | 11 | $2,061 | $187 |
2018: 7 services
| Return visit (30+ min) | 112 | $11,833 | $83 |
| Diagnostic exam of nasal passages using an endoscope | 42 | $8,669 | $184 |
| New patient visit (30+ min) | 102 | $8,455 | $83 |
| New patient visit (45+ min) | 60 | $7,946 | $132 |
| Diagnostic exam of voice box using a flexible endoscope | 53 | $5,047 | $93 |
| Short return visit (20+ min) | 53 | $4,226 | $60 |
| Removal of impacted ear wax | 14 | $540 | $36 |
2017: 9 services
| New patient visit (30+ min) | 178 | $15,538 | $87 |
| Return visit (30+ min) | 91 | $9,158 | $88 |
| Diagnostic exam of nasal passages using an endoscope | 39 | $6,891 | $177 |
| Diagnostic exam of voice box using a flexible endoscope | 41 | $3,895 | $89 |
| New patient visit (45+ min) | 23 | $3,071 | $134 |
| Short return visit (20+ min) | 51 | $3,003 | $57 |
| Removal of impacted ear wax | 37 | $1,385 | $36 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,249 | $83 |
| Diagnostic exam of voice box using a flexible endoscope | 14 | $862 | $57 |
2016: 3 services
| Short return visit (20+ min) | 21 | $1,580 | $63 |
| New patient visit (30+ min) | 17 | $1,521 | $89 |
| Removal of impacted ear wax | 19 | $820 | $43 |
2015: 1 service
| New patient visit (30+ min) | 14 | $804 | $57 |
Drugs they prescribed that Part D paid
$742
Pharmacies billed $742 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
39 generic and 0 brand-name prescriptions · $742 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Azelastine | 11 | $377 | $34 |
| Fluticasone Propionate | 11 | $106 | $10 |
Year by year
| 2024 | 39 | 19 | None | 0% | $742 |
| 2023 | 71 | 34 | None | None | $2,096 |
| 2022 | 118 | 55 | None | None | $3,688 |
| 2021 | 153 | 82 | None | None | $5,563 |
| 2020 | 179 | 85 | None | None | $4,128 |
| 2019 | 259 | 121 | 6% (15) | None | $6,735 |
| 2018 | 281 | 133 | 5% (15) | None | $6,605 |
| 2017 | 325 | 141 | None | None | $7,648 |
| 2016 | 504 | 182 | None | 10% | $17,433 |
| 2015 | 198 | 100 | 10% (20) | 8% | $5,537 |
| 2014 | 78 | 41 | 39% (30) | None | $941 |
| 2013 | 74 | 45 | 47% (35) | None | $1,468 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Fluticasone Propionate | 28 | $646 | $23 |
| Azelastine | 19 | $534 | $28 |
2022: 2 drugs
| Azelastine | 18 | $1,072 | $60 |
| Fluticasone Propionate | 48 | $921 | $19 |
2021: 3 drugs
| Azelastine | 20 | $1,324 | $66 |
| Fluticasone Propionate | 33 | $601 | $18 |
| Omeprazole | 16 | $179 | $11 |
2020: 3 drugs
| Fluticasone Propionate | 48 | $830 | $17 |
| Azelastine | 15 | $646 | $43 |
| Omeprazole | 25 | $207 | $8 |
2019: 8 drugs
| Azelastine | 21 | $1,322 | $63 |
| Fluticasone Propionate | 89 | $1,254 | $14 |
| Ipratropium | 14 | $413 | $30 |
| Triamcinolone Acetonide | 14 | $342 | $24 |
| Amoxicillin-Clavulanate Potass | 11 | $147 | $13 |
| Omeprazole | 17 | $125 | $7 |
| Hydrocodone-Acetaminophen | 14 | $74 | $5 |
| Cephalexin | 11 | $51 | $5 |
2018: 7 drugs
| Fluticasone Propionate | 102 | $1,278 | $13 |
| Azelastine | 28 | $764 | $27 |
| Triamcinolone Acetonide | 15 | $663 | $44 |
| Ipratropium | 11 | $458 | $42 |
| Omeprazole | 18 | $134 | $7 |
| Methylprednisolone | 13 | $117 | $9 |
| Hydrocodone-Acetaminophen | 12 | $58 | $5 |
2017: 5 drugs
| Fluticasone Propionate | 155 | $2,077 | $13 |
| Azelastine | 15 | $532 | $35 |
| Ipratropium | 14 | $493 | $35 |
| Omeprazole | 33 | $442 | $13 |
| Meclizine | 17 | $106 | $6 |
2016: 7 drugs
| Ciprodex | 34 | $6,377 | $188 |
| Fluticasone Propionate | 234 | $2,649 | $11 |
| Triamcinolone Acetonide | 13 | $717 | $55 |
| Omeprazole | 78 | $639 | $8 |
| Nystatin | 11 | $333 | $30 |
| Amoxicillin-Clavulanate Potass | 18 | $232 | $13 |
| Levocetirizine Dihydrochloride | 11 | $114 | $10 |
2015: 6 drugs
| Ciprodex | 14 | $2,510 | $179 |
| Fluticasone Propionate | 61 | $824 | $14 |
| Omeprazole | 31 | $301 | $10 |
| Amoxicillin-Clavulanate Potass | 11 | $129 | $12 |
| Hydrocodone-Acetaminophen | 12 | $79 | $7 |
| Cephalexin | 18 | $70 | $4 |
2014: 2 drugs
| Hydrocodone-Acetaminophen | 20 | $191 | $10 |
| Cephalexin | 19 | $100 | $5 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 21 | $203 | $10 |
| Cephalexin | 16 | $116 | $7 |
Money from drug and device companies
$496 in 2025
| 2025 | 5 | 6 | None | $496 |
| 2024 | 7 | 13 | None | $957 |
| 2023 | 2 | 4 | None | $300 |
| 2022 | 3 | 6 | None | $611 |
| 2021 | 3 | 4 | None | $221 |
| 2020 | 2 | 3 | None | $108 |
| 2019 | 1 | 1 | None | $52 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | None | $155 | 1 payment
|
| Abbvie | Botox | $150 | 1 payment
|
| Stryker | Xpress Loprofile | $140 | 2 payments
|
| KLS-Martin L.P. | None | $29 | 1 payment
|
| Integra LifeSciences | Acclarent Aera | $22 | 1 payment
|
See all 6 published payments
| KLS-Martin L.P. | Meals · 2025-11-26 | None | $29 |
| Medtronic | Meals · 2025-10-11 | None | $155 |
| Stryker | Meals · 2025-09-18 | Xpress Loprofile | $96 |
| Stryker | Meals · 2025-09-15 | Xpress Loprofile | $44 |
| Integra LifeSciences | Meals · 2025-06-13 | Acclarent Aera | $22 |
| Abbvie | Meals · 2025-03-18 | Botox | $150 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $957
| Aerin Medical | Vivaer Stylus | $284 | 2 payments
|
| Inspire Medical Systems | Inspire | $195 | 2 payments
|
| Stryker | Scopis Ent | $189 | 3 payments
|
| Integra LifeSciences | Integra | $135 | 2 payments
|
| 3-D Matrix | None | $73 | 1 payment
|
| KLS-Martin L.P. | None | $53 | 2 payments
|
| GlaxoSmithKline | Nucala | $28 | 1 payment
|
2023: $300
| Aerin Medical | Vivaer Stylus | $274 | 3 payments
|
| Integra LifeSciences | Integra | $26 | 1 payment
|
2022: $611
| Aerin Medical | None | $463 | 3 payments
|
| Acclarent | Trudi Nav Cable | $124 | 2 payments
|
| Integra LifeSciences | Integra | $25 | 1 payment
|
2021: $221
| Aerin Medical | Vivaer Stylus | $152 | 1 payment
|
| Integra LifeSciences | Amnioexcel | $46 | 2 payments
|
| Optinose US | Xhance | $23 | 1 payment
|
2020: $108
| Stryker | Entellus - Fiagon Sinus Navigation System | $63 | 1 payment
|
| OptiNose US | Xhance | $45 | 2 payments
|
2019: $52
| Stryker | Entellus - Fiagon Sinus Navigation System | $52 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588954937
- Licence
- CA A116546California A116546: Current · expires 2028-09-30
- Trained
- Boston University School of Medicine, 2009
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Otolaryngology (207Y00000X)
- Mailing address
- 5525 Etiwanda Ave, Ste 312, Tarzana, CA, 91356
- NPI first listed
- 2011-04-19
- NPI last updated
- 2015-04-27
This is when the NPI record was last certified, not a medical board exam.